1st São Paulo School of Translational Science |
-
Institution
Hospital A C Camargo. Fundação Antonio Prudente
-
Field of Knowledge
Genetics
-
Academic Director
Emmanuel Dias-Neto
-
Grant Number
2009/54527-4
-
Date
2010-04-19 to 2010-04-30
-
Registration Deadline
closed
-
Site
-
City
São Paulo
-
Keywords
Neuroscience, Translational science, Cancer, Angiogenesis, Metastasis, Genomics
-
Program
Hide
April 19th – Monday
9:00 – 10:00 AM
Registration and welcome breakfast
10:00 - 11:00 AM
Opening section: RR Brentani: Research and teaching at a private hospital.
11:00 – 11:45 AM
CH Brito-Cruz: FAPESP: Science and Technology in São Paulo.
11:45 – 12:30 PM
R Pasqualini: Mapping molecular diversity by in vivo phage display.
12:30 – 2:30 PM
Lunch
2:30 – 3:15 PM
W Arap: The human vascular mapping project.
3:15 – 4:00 PM
R Drmanac: Medical genomics as the foundation of personalized disease prevention and treatments
4:00 – 4:20 PM
Coffee break
4:20 – 5:05 PM
R Seeley: How obesity went to our heads: CNS regulation of energy balance
5:30 PM
Welcome cocktail
April 20th – Tuesday
9:00 – 9:45 AM
W Cavenee: Improving cancer therapy targeted at mutant receptors
9:45 – 10:30 AM
W Arap: Ligand-directed targeting and molecular imaging in translational medicine
10:30 – 10:50 AM
Coffee break
10:50 – 11:35 AM
R Drmanac: Understanding genetic and molecular basis of human diseases by sequencing one million human genomes
11:35 – 12:20 PM
R Seeley: Gut-brain communication in obesity and diabetes
12:20 – 1:40 PM
Lunch1:40 – 3:20 PM
Selected oral presentations
- Sergio Iadevaia, MD Anderson Cancer Center, Houston, USA: Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis.
- Avaduth Joshi, Johns Hopkins University, Baltimore, USA: Combined receptor tyrosine kinase inhibition of glioblastoma multiforme.
- Alexandre JN Trindade, Universidade Técnica de Lisboa, Lisboa, Portugal: DLL4 inhibition therapy can accelerate wound healing by inducing functional neo-angiogenesis: a matter of dosage.
3:20 – 3:45 PM
Coffee break
3:45 – 4:30 PM
R Pasqualini: Vascular and lymphatic targeting: pre-clinical and clinical drug development updates
April 21st – Wednesday
9:00 -9:45 AM
VR Martins: Prions: infectious mechanism and diseases
9:45 – 10:30 AM
R Linden: The prion protein and the immune system - and the other way around
10:30 – 11:00 AM
Coffee break
11:00 – 11:45 AM
MA Prado: Yin and Yang of prion protein biology.
11:45 – 1:00 PM
Selected oral presentations
- Flavio HB Paiva, Robarts Res. Institute, London, Canada: Prion protein transduces signals after binding to laminin chain via metabrotopic glutamate receptors.
- Bruno Costa da Silva, Ludwig Institute for Cancer Research, São Paulo, Brazil: Functional relevance of cellular prion protein (PrPC) and Hsp70/Hsp90 organizing protein (STI1/HOP) in colorectal and pancreatic tumors.
- Ana Cristina R Magalhães, Robarts Res. Institute, London, Canada: CRF receptor 1 regulates anxiety behaviour via sensitization of 5-HT2 receptor signaling.
- Maria Galli de Amorim, Philadelphia, USA: Modeling Rett syndrome with genetically modified mice.
1:00 – 2:00 PM
Lunch
2:00 – 2:45 PM
VR Martins: Prion protein as a therapeutic target in cancer
2:45 – 3:30 PM
R Linden: Neuroprotection by the transcription factor Max: Towards gene therapy for glaucoma
3:30 – 4:15 PM
Coffee break
4:15 – 5:00 PM
MA Prado: The use of genetically modified mice to model and understand human diseases.
April 22nd – Thursday
9:00 -9:45 AM
A Bardelli: The genetic basis of response to EGFR targeted therapies in CRCs.
9:45 – 10:45 AM
Oral Presentations
- Rachid A. Karam, University of California San Diego, San Diego, USA: Coupling of RNA and protein quality controls in cancer.
- Curtis Pickering, MD Anderson Cancer Center, Houston, USA: Profiling tongue squamous cell carcinoma to understand tumor formation, lymph node metastasis and drug resistance.
- Gustavo de Campos Molina, Hospital AC Camargo, São Paulo, Brazil: Combination of an enzyme restriction and barcode method for transcriptional assessment in 454-platform.
10:45 – 11:15 AM
Coffee break
11:15 – noon
SR Rogatto: Integrative genomic and transcriptomic analysis of uterine leyomiomas
noon – 12:45 PM
P Stankiewicz: Mechanisms of DNA rearrangements underlying genomic disorders
12:45- 1:45
Lunch
1:45 – 2:15
Oral presentations:
- Francine Blumental de Abreu, Hospital AC Camargo, São Paulo, Brazil: 3p12.3 and 7q36.3 harbor genes associated with hereditary breast and colorectal carcinomas.
- Melanie Heney, Baylor College of Medicine, Houston, USA: Using a mouse copy number variation (CNV)-engineering system to study neurobehavioral and metabolic phenotypes in two genomic disorders SMS and PTLS
2:15 – 3:00 PM
P Stankiewicz: Molecular mechanisms and clinical consequences of genomic disorders.
3:00 – 3:45 PM
C Rosenberg : Advances in the diagnosis of mental retardation: from karyotyping to molecular cytogenetics.
3:45 – 4:15 PM
Coffee break
4:15 – 5:00 PM
SR Rogatto: Copy number alterations in hereditary breast and colorectal cancer syndromes
April 23rd – Friday
9:00 -9:45 AM
A Bardelli: Isogenic mutant human cells: A new tool for personalized cancer medicine.
9:45 – 10:30 AM
D Lyden: The switch between angiogenesis and vasculogenesis for tumor growth and metastases
10:30 – 10:50 AM
Coffee break
10:50 – 11:35 AM
D Lyden: The pre-metastatic niche: a permissive microenvironment for metastasis.
11:35 – 12:20 PM
A Coutinho: Mechanisms of natural immunological tolerance: implications for cancer immunotherapy
12:20 - 1:05 PM
A Coutinho: Integrating evolutionary layers of host protection: immunity and tolerance
Free Afternoon
April 26th – Monday9:45 – 10:30 AM
O Podhajcer: Role of matricellular protein in cancer progression.
10:30 – 10:50 AM
Coffee break
10:50 – 11:35 AM
LP Kowalski: Oropharynx cancer: chemoradiation or surgery?
11:35 – 12:20 PM
A Lopes: Penile carcinoma, clinical aspects, treatment and prognostic factors
12:20 – 1:30 PM
Lunch
1:30 – 2:30 PM
Oral Presentations
- Di Ai, University of Texas, Houston, USA: Cardiomyocyte PDGFR-b signaling is an essential component of the mouse cardiac response to load-induced stress.
- Márcio L. Acêncio, UNESP, Botucatu, Brazil: In silico network-based discovery of candidate RB-E2F axis-independent signaling pathways involved in the cell-matrix adhesion-mediated control of G1/S cell cycle transition.
- Carla Abdo Brohem, Universidade de São Paulo, São Paulo, Brazil: Mechanism of action of 4-nerolidylcathecol: induction of apoptosis via ROS accumulation and inhibition of invasion in melanoma and skin reconstructs model.
- Mauro SG Pavão, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil: oversulfated dermatan sulfate from ascidians, but not its mammalian counterpart, inhibits p-selectin in vitro and metastasis in vivo.
2:30 – 3:15 PM
J Kobarg: The role of Nek family kinases in cell cycle progression and DNA damage responses.
3:15 – 3:45 PM
Coffee break
3:45 – 4:30 PM
S Rehen: Embryonic and pluripotent stem cells as tools for studying neurogenesis
4:30 – 5:15 PM
R Chammas: Functional significance of carbohydrate-dependent tumor associated antigens
5:15 – 6:00 PM
FA Soares: Morphological aspects of the EMT phenomenon
April 27th - Tuesday
9:00 -9:45 AM
Bettina Weigelin, Nijmegen, Netherlands: Dynamic imaging of the tumor microenvironment: impact on invasion and CTL effector function.
9:45 – 10:30 AM
J Kobarg: The human microtubule transport adaptor protein FEZ1 is involved in the formation of “flower-like” nuclei.
10:30 – 10:50 AM
Coffee break
10:50 – 11:35 AM
S Rehen: Neural differentiation is followed by aneuploidy in embryonic and induced pluripotent cells
11:35 – 12:50 PM
Oral presentations
- Luciane Fragel Madeira, Universidade Federal Fluminense, Rio de Janeiro, Brazil: A check-point induced by platelet activating factor arrests retinal progenitors at the S/G2 cell cycle transition.
- Patrícia M. Machado, Instituto Português de Oncologia de Lisboa, Lisboa, Portugal: BRCA1/2 genetic screening in Portuguese high-risk breast/ovarian cancer families.
- Alisson M Burton, MD Anderson Cancer Center, Houston, USA: Health and life-style behaviors among persons at risk for Lynch syndrome.
- Edenir Inez Palmero, Hospital de Câncer de Barretos, Barretos, Brazil: TP53, PIN3 and MDM2 SNP309 polymorphism as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis.
- Sofia Braga, Instituto Gulbenkian de Ciência, Oeiras, Portugal: Heterogeneity of triple negative breast cancer.
12:50 – 1:50 PM
Lunch
1:50 – 2:35 PM
P Hainaut: TP53 suppressor gene: from genomics to clinical applications.
2:35 – 3:20 PM
MI Achatz: Managing families with inherited cancer; High prevalence of R337H mutation in Brazilian LFS/LFL families.
3:20 – 3:50 PM
Coffee break
3:50 – 4:35 PM
P Ashton-Prolla: Genetic counseling in inherited predisposition cancer syndromes
4:35 – 5:20 PM
D Malkin: The role of DNA copy number variation in childhood cancer susceptibility.
5:20 – 6:05 PM
FA Soares: Tumor differentiation – phenotypic/genotypic relationships
April 28th – Wednesday (new)
9:30 – 10:15 AM
O Podhajcer: Oncolytic vectors in cancer therapy
10:15 – 10:30 AM
Coffee break
10:30 – 11:15 AM
R Tuder: Interplay between alveolar cell apoptosis, oxidative stress, and senescence in cigarette smoke-induced pulmonary diseases
11:15 – 12:15 PM Oral presentations
- Cintia Yoko Morioka, Toyama Medical and Pharmaceutical University, Toyama, Japan. Anti-sense oligonucleotide matching k-ras gene in hamster pancreatic cancer model in-vitro and in-vivo – Is it possible?
- Pedro MP Coelho, Depto de Anatomia, Univ. Federal do Rio de Janeiro, Rio de Janeiro, Brazil. Cell therapy in a rodent model of neonatal hypoxic-ischemic encephalopathy.
- Agda Karina Eterovic, University of Texas Health Science Center, Houston, USA. Mediators of glioblastoma resistance and invasion during anti-VEGF therapy.
- Valerie LeBleu, Harvard Medical School Boston, USA. Disruption of tumor angiogenesis leads to increased metastasis due to HIF1a/CD44/p38 MAP kinase mediated epithelial to mesenchymal transition.
12:15 – 1:30 PM
Lunch
1:30 – 2:15 PM
R Kalluri: Systemic angiogenesis balance and tumor microenvironment.
2:15 – 3:00 PM
R Tuder: Abnormal angiogenesis and disregulated growth of pulmonary endothelial cells in pulmonary hypertension.
3:00 – 3:30 PM
Coffee break
3:30 – 4:15 PM
R Giordano: Development of anti-angiogenic compounds: Phage-display and the angiogenic retina as a model
4:15 – 5:00 PM
I Izquierdo: Memory consolidation
5:00 – 5:45 PM
DI Smith: Developing the infrastructure for next-generation DNA sequencing at the Mayo clinic
April 29th – Thursday
9:00 -9:45 AM
R Costa: Neural mechanisms of action learning: from intent to habit
9:45 – 10:30 AM
Z Mainen: Sensory perception: Lessons from the olfactory system of the rat
10:30 – 11:00 AM
Coffee break
11:00 – 12:15 AM
Oral presentations
- Angela A. Fachel, Universidade de Sao Paulo, Sao Paulo, Brazil. Long intronic non-coding RNA signatures of malignancy and survival outcome in clear cell renal carcinoma.
- Barbara Pereira de Melo, Hospital AC Camargo, Sao Paulo, Brazil. No-match ORESTES explored as non-coding tumor markers.
- Gustavo J. Rodrigues, Baylor College of Medicine, Houston, USA. Allosteric communication within the dopamine D2 receptor: evolution-guided retooling receptor activation specificity.
- Frederico R. Ferreira, Faculdade de Medicina, Universidade de Sao Paulo, Ribeirao Preto, Brazil. Effects of treatment with 7-nitroindazole (7NI), a neuronal NO synthase inhibitor, or imipramine on protein and gene expression in the hippocampus of rats submitted to the forced swimming test.
- Janine Inez Rossato, Instituto do Cérebro, PUC-RS, Porto Alegre, Brazil. On the reconsolidation of extinction memory.
12:15 – 1:30 PM
Lunch
1:30 – 2:15 PM
V Moura-Neto: Cross-talk between parenchyma and glial cells: highlights in brain tumors
2:15 – 3:00 PM
I Izquierdo: Memory persistence I
3:00 – 3:45 PM
I Izquierdo: Memory persistence II
3:45 – 4:15 PM
Coffee break
4:15 – 5:00 PM
R Costa: Generating action sequences
5:00 – 5:45 PM
Z Mainen: Decision-making: Executing and monitoring decisions under uncertainty
5:45 – 6:45 PM
Diego Olego: Technical innovations in oncology